Clinical Utility of Pharmacogenomic Data Collected by a Health-System Biobank to Predict and Prevent Adverse Drug Events
- 23 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Drug Safety
- Vol. 44 (5), 601-607
- https://doi.org/10.1007/s40264-021-01050-6
Abstract
Introduction Medication-related harm represents a significant issue for patient safety and quality of care. One strategy to avoid preventable adverse drug events is to utilize patient-specific factors such as pharmacogenomics (PGx) to individualize therapy. Objective We measured the number of patients enrolled in a health-system biobank with actionable PGx results who received relevant medications and assessed the incidence of adverse drug events (ADEs) that might have been prevented had the PGx results been used to inform prescribing. Methods Patients with actionable PGx results in the following four genes with Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines were identified: HLA-A*31:01, HLA-B*15:02, TPMT, and VKORC1. The patients who received interacting medications (carbamazepine, oxcarbazepine, thiopurines, or warfarin) were identified, and electronic health records were reviewed to determine the incidence of potentially preventable ADEs. Results Of 36,424 patients with PGx results, 2327 (6.4%) were HLA-A*31:01 positive; 3543 (9.7%) were HLA-B*15:02 positive; 2893 (7.9%) were TPMT intermediate metabolizers; and 4249 (11.7%) were homozygous for the VKORC1 c.1639 G>A variant. Among patients positive for one of the HLA variants who received carbamazepine or oxcarbazepine (n = 92), four (4.3%) experienced a rash that warranted drug discontinuation. Among the TPMT intermediate metabolizers who received a thiopurine (n = 56), 11 (19.6%) experienced severe myelosuppression that warranted drug discontinuation. Among patients homozygous for the VKORC1 c.1639 G>A variant who received warfarin (n = 379), 85 (22.4%) experienced active bleeding and/or international normalized ratio (INR) > 5 that warranted drug discontinuation or dose reduction. Conclusion Patients with actionable PGx results from a health-system biobank who received relevant medications experienced predictable ADEs. These ADEs may have been prevented if the patients’ PGx results were available in the electronic health record with clinical decision support prior to prescribing.Keywords
This publication has 27 references indexed in Scilit:
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 UpdateClinical Pharmacology & Therapeutics, 2017
- Integrating pharmacogenomics into electronic health records with clinical decision supportAmerican Journal of Health-System Pharmacy, 2016
- US Emergency Department Visits for Outpatient Adverse Drug Events, 2013-2014JAMA, 2016
- Implementing Pharmacogenomics at Your Institution: Establishment and Overcoming Implementation ChallengesClinical and Translational Science, 2016
- Medical error—the third leading cause of death in the USBMJ, 2016
- The Outlier in All of Us: Why Implementing Pharmacogenomics Could Matter for EveryoneClinical Pharmacology & Therapeutics, 2016
- Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical CentersAnnual Review of Pharmacology and Toxicology, 2015
- Clinically Actionable Genotypes Among 10,000 Patients With Preemptive Pharmacogenomic TestingClinical Pharmacology & Therapeutics, 2013
- ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencingGenetics in Medicine, 2013
- Medication-related Clinical Decision Support in Computerized Provider Order Entry Systems: A ReviewJournal of the American Medical Informatics Association, 2007